Key facts
- It has raised $37.9M; the latest was Later Stage VC ($18.0M) in Oct 2025.
- Notable investors include Tech Incubator Program for Startup, KB Investment, Smilegate Investment, Posco Investment, iM Investment Partners — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for MediMabBio
- ·The full record, as it builds
Funding rounds
No funding rounds for MediMabBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MediMabBio
Developer of healthcare immunotherapies designed to treat serious diseases such as cancer and autoimmune disorders. The company offers engineered monoclonal antibodies, cytokine-antibody fusion proteins, and T-cell-targeted biologics, enabling pharmaceutical collaborators and clinical researchers to access next-generation immuno-oncology candidates and biologics with precision-designed functionalities.
- Sector
- Healthcare
- HQ
- Seongnam, South Korea
- Founded
- 2017
- Employees
- 16
- Website
- medimabbio.com/
- Ownership
- Privately Held (backing)
MediMabBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MediMabBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MediMabBio in its N-PORT filings yet. We sweep new filings monthly.